Description

Associated products

Specifications

Our Abpromise guarantee covers the use of ab180923 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

  • Applications

    Blocking - Blocking peptide for Anti-Cytokeratin 13 antibody [EPR3671] (ab92551)

  • Form

    Liquid
  • Additional notes

    - First try to dissolve a small amount of peptide in either water or buffer. The more charged residues on a peptide, the more soluble it is in aqueous solutions.
    - If the peptide doesn’t dissolve try an organic solvent e.g. DMSO, then dilute using water or buffer.
    - Consider that any solvent used must be compatible with your assay. If a peptide does not dissolve and you need to recover it, lyophilise to remove the solvent.
    - Gentle warming and sonication can effectively aid peptide solubilisation. If the solution is cloudy or has gelled the peptide may be in suspension rather than solubilised.
    - Peptides containing cysteine are easily oxidised, so should be prepared in solution just prior to use.

  • Concentration information loading...

Preparation and Storage

  • Stability and Storage

    Shipped at 4°C. Store at 4°C (stable for up to 12 months). Upon delivery aliquot. Store at -20°C long term.

General Info

  • Alternative names

    • 47 kDa cytokeratin
    • CK-13
    • CK13
    • Cytokeratin 13
    • Cytokeratin-13
    • K13
    • K1C13_HUMAN
    • Ka13
    • Keratin
    • Keratin 13
    • keratin type I cytoskeletal 13
    • Keratin-13
    • Krt-1.13
    • Krt1-13
    • KRT13
    • MGC161462
    • MGC3781
    • type I cytoskeletal 13
    • Type I keratin Ka13
    • WSN2
    see all
  • Tissue specificity

    Expressed in some epidermal sweat gland ducts (at protein level) and in exocervix, esophagus and placenta.
  • Involvement in disease

    Defects in KRT13 are a cause of white sponge nevus of cannon (WSN) [MIM:193900]. WSN is a rare autosomal dominant disorder which predominantly affects non-cornified stratified squamous epithelia. Clinically, it is characterized by the presence of soft, white, and spongy plaques in the oral mucosa. The characteristic histopathologic features are epithelial thickening, parakeratosis, and vacuolization of the suprabasal layer of oral epithelial keratinocytes. Less frequently the mucous membranes of the nose, esophagus, genitalia and rectum are involved.
  • Sequence similarities

    Belongs to the intermediate filament family.
  • Post-translational
    modifications

    O-glycosylated; glycans consist of single N-acetylglucosamine residues.
  • Information by UniProt

References

ab180923 has not yet been referenced specifically in any publications.

Customer reviews and Q&As

There are currently no Customer reviews or Questions for ab180923.
Please use the links above to contact us or submit feedback about this product.

Please note: All products are "FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC PROCEDURES"
For licensing inquiries, please contact partnerships@abcam.com

Sign up